ALX Oncology Holdings Inc. logo

ALX Oncology Holdings Inc.

NASDAQ:ALXO

Overview | Financials
Company Name ALX Oncology Holdings Inc.
Symbol ALXO
Currency USD
Price 1.83
Market Cap 96,519,873
Dividend Yield 0%
52-week-range 1.19 - 17.825
Industry Biotechnology
Sector Healthcare
CEO Mr. Jason W. Lettmann
Website https://www.alxoncology.com

An error occurred while fetching data.

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's

Related Stocks

Absci Corporation logo

Absci Corporation

ABSI

3.01 USD

HilleVax, Inc. logo

HilleVax, Inc.

HLVX

1.87 USD

Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc.

HRTX

1.58 USD

BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc.

BTAI

0.351 USD

Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc.

FULC

4.55 USD

C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc.

CCCC

3.87 USD

OraSure Technologies, Inc. logo

OraSure Technologies, Inc.

OSUR

3.69 USD

EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc.

EYPT

7.33 USD

Athira Pharma, Inc. logo

Athira Pharma, Inc.

ATHA

0.542 USD

Financials

Numbers are in millions USD

Numbers are in millions USD